Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
11 - Hematopoietic cell transplantation for myelofibrosis: who and when?
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 86 - 96Publisher: Cambridge University PressPrint publication year: 2016
References
Mesa, RA. Assessing new therapies and their overall impact in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2010;2010:115–21.Google ScholarPubMed
Gupta, V, Hari, P, Hoffman, R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012;120(7):1367–79.CrossRefGoogle ScholarPubMed
Cervantes, F, Dupriez, B, Pereira, A, Passamonti, F, Reilly, JT, Morra, E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901.CrossRefGoogle Scholar
Passamonti, F, Cervantes, F, Vannucchi, AM, Morra, E, Rumi, E, Pereira, A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8.CrossRefGoogle Scholar
Gangat, N, Caramazza, D, Vaidya, R, George, G, Begna, K, Schwager, S, et al. DIPSS Plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.CrossRefGoogle Scholar
Tefferi, A, Pardanani, A, Gangat, N, Begna, KH, Hanson, CA, Van Dyke, DL, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia. 2012;26(6):1439–41.CrossRefGoogle ScholarPubMed
Vannucchi, AM, Lasho, TL, Guglielmelli, P, Biamonte, F, Pardanani, A, Pereira, A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–9.CrossRefGoogle ScholarPubMed
Lundberg, P, Karow, A, Nienhold, R, Looser, R, Hui, HS, Nissen, I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–8.CrossRefGoogle ScholarPubMed
Guglielmelli, P, Lasho, TL, Rotunno, G, Score, J, Mannarelli, C, Pancrazzi, A, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28(9):1804–10.CrossRefGoogle Scholar
Vannucchi, AM, Rotunno, G, Bartalucci, N, Raugei, G, Carrai, V, Balliu, M, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia. 2014;28(9):1811–18.CrossRefGoogle ScholarPubMed
Gupta, V, Malone, AK, Hari, PN, Ahn, KW, Hu, ZH, Gale, RP, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2014;20(1):89–97.CrossRefGoogle ScholarPubMed
Gupta, V, Kroger, N, Aschan, J, Xu, W, Leber, B, Dalley, C, et al. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant. 2009;44(5):317–20.CrossRefGoogle ScholarPubMed
Abelsson, J, Merup, M, Birgegard, G, Weisbjerrum, O, Brinch, L, Brune, M, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant. 2012;47(3):380–6.CrossRefGoogle ScholarPubMed
Patriarca, F, Bacigalupo, A, Sperotto, A, Isola, M, Soldano, F, Bruno, B, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93(10):1514–22.CrossRefGoogle ScholarPubMed
Abelsson, J, Merup, M, Birgegard, G, WeisBjerrum, O, Brinch, L, Brune, M, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant. 2012;47(3):380–6.CrossRefGoogle ScholarPubMed
Kroger, N, Holler, E, Kobbe, G, Bornhauser, M, Schwerdtfeger, R, Baurmann, H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264–70.Google ScholarPubMed
Rondelli, D, Goldberg, JD, Isola, L, Price, LS, Shore, TB, Boyer, M, et al. MPD-RC 101 prospective study of reduced intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124 (7):1183–91.CrossRefGoogle ScholarPubMed
Verstovsek, S, Mesa, RA, Kantarjian, HM. Ruxolitinib for myelofibrosis reply. N Engl J Med. 2012;366(21):2034.Google Scholar
Harrison, C, Kiladjian, JJ, Barosi, G. Ruxolitinib for myelofibrosis reply. N Engl J Med. 2012;366(21):2032–4.Google Scholar
Spoerl, S, Mathew, NR, Bscheider, M, Schmitt-Graeff, A, Chen, S, Mueller, T, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832–42.CrossRefGoogle ScholarPubMed
Heine, A, Held, SAE, Daecke, SN, Wallner, S, Yajnanarayana, SP, Kurts, C, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192–202.CrossRefGoogle ScholarPubMed
Rudolph, J, Schonberg, K, Brossart, P, Wolf, D. The JAK inhibitor ruxolitinib substantially affects NK biology. Haematologia. 2014;99(Suppl. 1).Google Scholar
Jaekel, N, Behre, G, Behning, A, Wickenhauser, C, Lange, T, Niederwieser, D, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49(2):179–84.CrossRefGoogle ScholarPubMed
Stubig, T, Alchalby, H, Ditschkowski, M, Wolf, D, Wulf, G, Zabelina, T, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28(8):1736–8.CrossRefGoogle ScholarPubMed
Robin, M, Francois, S, Huynh, A, Cassinat, B, Bay, JO, Cornillon, J, et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the SFGMTC. Blood. 2013;122(21).CrossRefGoogle Scholar
Shanavas, M, Messner, HA, Atenafu, EG, Kim, DH, Kuruvilla, J, Lipton, JH, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. Bone Marrow Transplant. 2014;49(9):1162–9.CrossRefGoogle ScholarPubMed
Kremyanskaya, M, Mascarenhas, J, Rampal, R, Hoffman, R. Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. Br J Haematol. 2014;167(1):144–6.CrossRefGoogle ScholarPubMed
Verstovsek, S, Mesa, RA, Gotlib, J, Levy, RS, Gupta, V, DiPersio, JF, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479–88.CrossRefGoogle ScholarPubMed
Koreth, J, Pidala, J, Perez, WS, Deeg, HJ, Garcia-Manero, G, Malcovati, L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of Clinical Oncology. 2013;31(21):2662.CrossRefGoogle ScholarPubMed
Cutler, CS, Lee, SJ, Greenberg, P, Deeg, HJ, Perez, WS, Anasetti, C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579–85.CrossRefGoogle ScholarPubMed
Santos, FPS, Tam, CS, Kantarjian, H, Cortes, J, Thomas, D, Pollock, R, et al. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. 2014;55(1):121–7.CrossRefGoogle ScholarPubMed
Robin, M, Esperou, H, de Latour, RP, Petropoulou, AD, Xhaard, A, Ribaud, P, et al. Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis. Br J Haematol. 2010;150(6):721–4.CrossRefGoogle ScholarPubMed
Ballen, KK, Shrestha, S, Sobocinski, KA, Zhang, MJ, Bashey, A, Bolwell, BJ, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010;16(3):358–67.CrossRefGoogle ScholarPubMed
Scott, BL, Gooley, TA, Linenberger, ML, Sandmaier, BM, Myerson, D, Chauncey, T, et al. International working group scores predict post-transplant outcomes in patients with myelofibrosis. Blood. 2010;116(21):1272-.CrossRefGoogle Scholar
Kroger, N, Holler, E, Kobbe, G, Bornhauser, M, Schwerdtfeger, R, Baurmann, H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264–70.Google ScholarPubMed
Murata, M, Nishida, T, Taniguchi, S, Ohashi, K, Ogawa, H, Fukuda, T, et al. Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT. Bone Marrow Transplant. 2014;49(3):355–60.CrossRefGoogle ScholarPubMed
Robin, M, Giannotti, F, Deconinck, E, Mohty, M, Michallet, M, Sanz, G, et al. Outcomes after unrelated cord blood transplantation for adults with primary or secondary myelofibrosis: a retrospective study on behalf of Euro cord and Chronic Malignancy Working Party-EBMT. Blood. 2013;122(21).CrossRefGoogle Scholar
Askaa, B, Fischer-Nielsen, A, Vindelov, L, Haastrup, EK, Sengelov, H. Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning. Bone Marrow Transplant. 2014;49(5):720–1.CrossRefGoogle ScholarPubMed
Tefferi, A, Cervantes, F, Mesa, R, Passamonti, F, Verstovsek, S, Vannucchi, AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395–8.CrossRefGoogle ScholarPubMed
Alchalby, H, Badbaran, A, Bock, O, Fehse, B, Bacher, U, Zander, AR, et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant. 2010;45(9):1404–7.CrossRefGoogle ScholarPubMed
Klyuchnikov, E, El-Cheikh, J, Sputtek, A, Lioznov, M, Calmels, B, Furst, S, et al. CD34(+)-Selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2014;20(3):382–6.CrossRefGoogle ScholarPubMed
Klyuchnikov, E, Holler, E, Bornhauser, M, Kobbe, G, Nagler, A, Shimoni, A, et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol. 2012;159(2):172–81.CrossRefGoogle ScholarPubMed
Li, ZH, Gooley, T, Appelbaum, FR, Deeg, HJ. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood. 2001;97(7):2180–1.CrossRefGoogle ScholarPubMed
Kroeger, N, Holler, E, Kobbe, G, Bornhaeuser, M, Schwerdtfeger, R, Nagler, A, et al. Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a multicenter prospective trial of the chronic leukemia working party of the European group for Blood and Marrow Transplantation (EBMT). Blood. 2007;110(11):210a-a.Google Scholar
Bacigalupo, A, Soraru, M, Dominietto, A, Pozzi, S, Geroldi, S, Van Lint, MT, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 2010;45(3):458–63.CrossRefGoogle ScholarPubMed
Patriarca, F, Bacigalupo, A, Sperotto, A, Isola, M, Soldano, F, Bruno, B, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematol-Hematol J. 2008;93(10):1514–22.CrossRefGoogle ScholarPubMed
Shanavas, M, Gupta, V. Controversies and dilemmas in allogeneic transplantation for myelofibrosis. Best Pract Res Clin Haematol. 2014;27(2):165–74.CrossRefGoogle ScholarPubMed